The Latest Breaking News from Biogen Inc

The biotech industry seems poised to witness solid growth over the next decade with intensive innovation, breakthrough developments, and growing investments in the sector. So, given analysts’ promising growth outlook for the industry, it could be wise for investors to buy and hold fundamentally solid biotech stocks Vertex Pharmaceuticals (VRTX),…

Scholar Rock Holding Corp (NASDAQ:SRRK) announced new data from the Phase 2 TOPAZ trial extension period evaluating apitegromab in non-ambulatory patients with Types 2 and 3 Spinal Muscular Atrophy (SMA) receiving an SMN therapy. The trial assessed patient outcomes after 24 months of treatment.  All 35 non-ambulatory patients (Cohorts 2 and 3) and…

Biogen Inc. (NASDAQ:BIIB) has informed Karyopharm Therapeutics Inc (NASDAQ:KPTI) that it has opted to terminate the companies' Asset Purchase Agreement dated January 24, 2018, as amended. As per the agreement, Karyopharm sold rights of its oral Selective Inhibitor of Nuclear Export compound KPT-350 and certain related assets to Biogen. KPTI received an upfront payment…

Catalyst Biosciences Inc (NASDAQ:CBIO) has agreed to sell its portfolio of protease medicines that regulate complement to Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) for $60 million. "This sale is part of the ongoing strategic process that we announced in February to explore alternatives and create value for shareholders. We have significantly reduced our cash burn and continue…

Despite logistical hurdles, the biotech industry is expected to expand solidly in the coming years on lucrative federal investments and strong demand. Therefore, we think it could be wise to bet on the stocks of quality biotech companies Biogen (BIIB), BioNTech (BNTX), and Incyte (INCY). These stocks are rated ‘Buy’…

Eisai Co Ltd (OTC:ESALY) has completed the rolling submission of the FDA marketing application under the accelerated approval for lecanemab (BAN2401) for mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and mild AD. Eisai is collaborating with Biogen Inc (NASDAQ:BIIB) for drug development. Eisai has requested a Priority Review, while the lecanemab Phase 3…

Biogen Inc (NASDAQ:BIIB) posted Q1 sales of 2.53 billion, beating the consensus of $2.49 billion, down 6% Y/Y. Multiple sclerosis (MS) revenue, including royalties on sales of Ocrevus, of $1.79 billion decreased by 3%.  Spinraza's revenue of $441 million decreased 9% at actual currency and 6% at constant currency.  Aduhelm's revenue was…

Sage Therapeutics Inc (NASDAQ:SAGE) and Biogen Inc (NASDAQ:BIIB) have initiated a rolling submission of a marketing application to the FDA for zuranolone in major depressive disorder (MDD).  Zuranolone is an investigational two-week, once-daily oral drug developed for MDD and postpartum depression (PPD).  The companies have submitted the nonclinical module and plan to submit the remaining…

Biogen Inc’s (NASDAQ: BIIB) base business seems to be worth more than what the Street estimates, and it is possible that investors are not properly valuing royalty streams coming to the company, which contributes 15% of current revenues and 40% of the valuation, according to Wells Fargo.

Centers for Medicare and Medicaid Services (CMS) finalized its decision to restrict coverage for Biogen Inc's (NASDAQ:&

The U.S. Medicare program finalized a plan to only pay for Biogen Inc.’s Alzheimer’s therapy when it’s used in approved clinical trials, while offering a road map to cover drugs that do show clinical benefit in the disease.